Clinical endpoints for efficacy studies. Issue 34 (7th August 2019)

• Record Type: Journal Article
• Authors: Porter, Chad K.; Gutierrez, Ramiro L.; Kotloff, Karen L.
• Is Part Of: Vaccine. Volume 37:Issue 34(2019)
• Page Start: 4814
• Page End: 4822
• Publication Date: 2019-08-07
• Subjects: Controlled human infection model -- Shigella -- Enterotoxigenic E. coli -- ETEC -- Vaccine -- Endpoints -- Efficacy -- Diarrheal diseases -- Travelers' diarrhea -- CHIM; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2019.03.051
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Well-established, validated and clinically meaningful primary and secondary endpoints are critical in advancing vaccines through proof of principal studies, licensure and pre-qualification. To that end, the field of vaccine development for Shigella, enterotoxigenic Escherichia coli (ETEC) as well as other enteric pathogens would benefit greatly from a focused review of clinical endpoints and the use of common endpoints across the field to enable study-to-study comparisons as well as comparative assessments between vaccine candidates. A workshop was conducted to review clinical endpoints from controlled human challenge studies, field studies in naïve adult travelers and pediatric studies in low-middle income countries and to develop a consensus on clinical endpoints for future vaccine trials. Following sequential presentations on different study designs (CHIM, travelers' efficacy and pediatric efficacy), workshop participants broke into three simultaneous workgroups focused on those study designs to discuss a number of topics key to clinical endpoints specific to each study design. Previously utilized endpoints were reviewed with an eye towards potentially novel endpoints for future studies and consideration of the disease parameters and spectrum of disease targeted for prevention. The strength of support among workshop participants for the use of various endpoints is summarized as are recommendations for additional endpoints to be considered in future studies. It is anticipated that this report will facilitate endpoint determination in future efficacy trials of vaccine candidates.